If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
341
results.
Updated on
15/11/2026 [08:23:00]
Results 225 to 250 of 341
Absstract of: AU2024347751A1
The present invention provides various biomarkers for identifying patients that are likely to benefit from treatment with a TLR inhibitor.
Absstract of: WO2025050066A1
The present disclosure provides compositions for activating TERT expression and methods of using the same for treating or ameliorating aging, aging-related diseases, and neurodegenerative conditions.
Absstract of: US20260298958A1
Disclosed is a specimen analysis method for analyzing a specimen regarding a plurality of measurement items, the specimen analysis method comprising: measuring a first measurement item and a second measurement item on the basis of a measurement order; executing a process related to a time difference between a measurement of the first measurement item and a measurement of the second measurement item; and obtaining a calculation value from a measurement value of the first measurement item and a measurement value of the second measurement item.
Absstract of: US20260298913A1
0000 The present disclosure relates to a method for detecting an analyte present in trace amounts in a fluid sample. The method includes at least: causing a fluid sample containing an analyte to flow over a substrate having an array of microchambers, with a first capture substance that specifically binds to the analyte immobilized in the microchambers; binding the analyte to the first capture substance; causing a second capture substance, which specifically binds to the analyte and binds to a signal-generating substance, to flow over the substrate; causing the signal-generating substance to flow over the substrate to bind to the second capture substance; causing a substrate solution to flow over the substrate; causing a hydrophobic solvent to flow over the substrate to remove the substrate solution present outside the microchambers; and counting and detecting the number of microchambers in which the fluorescence signal is generated.
Absstract of: US20260294328A1
0000 Disclosed herein are methods for diagnosing Alzheimer's disease in a subject that involves administering to the subject an imaging agent comprising hyperpolarized pyruvate having a nuclear magnetic resonance (NMR)-detectable nucleus; applying radiation to the brain of the subject, wherein the radiation has a frequency that excites electron spin transitions in the DNP agent at an intensity to polarize the NMR-detectable nucleus; detecting magnetic resonance signals in the brain of the subject from nuclear spin transitions in the NMR-detectable nucleus to produce a spectrum measuring bicarbonate (Bic) and lactate (Lac) metabolites; and calculating a Bic/Lac ratio from the measured metabolites, wherein a reduced Bic/Lac ratio compared to control is an indication that the subject has Alzheimer's disease.
Absstract of: US20260297486A1
0000 Disclosed herein are 3D culture systems and methods for producing epithelial tubular organoids, such as intestinal organoids. Also disclosed is a screening method that involves contacting elongated epithelial tubes produced from the disclosed systems and methods with a candidate agent, culturing the elongated epithelial tube in a growth medium under growth conditions, and evaluating the elongated epithelial tube for a physiological effect.
Absstract of: CA3181040A1
0001 Systems for assessing and documenting changes in handwriting neurologic toxicity adverse events associated with a medical treatment (e.g., immune effector cell therapy) comprise a handwriting neurotoxicity grading criteria that defines the symptoms of at least one adverse event including micrographia, dysgraphia and agraphia. The handwriting neurotoxicity grading criteria may be included in a system for assessing immune effector cell associated movement and neurocognitive disorder, that comprises grading criteria for one or more of the symptom domains: handwriting impairment, gait impairment, other movement abnormalities of extremities, impairment in ability to perform ADLs, and impairment in expression or motivation. 0002 L'invention concerne des systèmes pour évaluer et documenter des changements dans des événements indésirables de toxicité neurologique d'écriture manuscrite associés à un traitement médical (par exemple, une thérapie cellulaire effectrice immunitaire), comprenant un critère de notation de neurotoxicité d'écriture manuscrite qui définit les symptômes d'au moins un événement indésirable comprenant la micrographitisation, la dysgraphitisation et l'agraphie. Les critères de notation de neurotoxicité d'écriture manuscrite peuvent être inclus dans un système pour évaluer un mouvement associé à une cellule effectrice immunitaire et un trouble neurocognitif, qui comprend des critères de classement pour un ou plusieurs des doma
Absstract of: US20260298946A1
The invention relates to a method for selecting a patient suffering stroke for a reperfusion therapy based on determining the level of retinol binding protein-4 (RBP4) and N-terminal fragment of B-type natriuretic peptide (NT-proBNP) in an isolated sample of said patient. The invention also relates to a method of differentiating ischemic stroke from haemorrhagic stroke and to kits comprising reagents to carry out the methods.
Absstract of: US20260298947A1
0000 A method for the in vitro diagnosis of a neurodegenerative disease, in a human or animal individual, at an early stage, including the step which includes in detecting the presence of at least one marker chosen from the derived forms of amyloid beta (Aβ) peptides selected from the oligomers of said peptides and the prefibrillar and fibrillar aggregated forms of said peptides, and the derived forms of phosphorylated tau proteins selected from the hyperphosphorylated forms of said proteins, the aggregated forms of said proteins and the modified phosphorylated tau proteins resulting from one or several post-translational modifications, the presence of the marker(s) being detected in a stool sample of said individual.
Absstract of: AU2025239644A1
Provided herein are medical uses of CD11a-enriched T regulatory cells for treating amyotrophic lateral sclerosis (ALS) or ameliorating a symptom of ALS. Such uses may include longitudinal analysis of biomarkers, such as inflammatory cytokines.
Absstract of: US20260298949A1
0000 Disclosed and claimed are compositions containing a calibrator and a stabilizer, wherein the stabilizer includes Diethylaminoethyl-(“DEAE”) dextran; D-Sorbitol, wherein the D-Sorbitol and DEAE-dextran are in a weight ratio from about 1:1 to about 5:2, a buffer; and a non-ionic surfactant; wherein the stabilizer is essentially free of bovine serum albumin; and wherein the calibrator is stabilized under frozen storage conditions, and remains stable when thawed and kept at temperatures of from about 2° C. to about 10° C. Also disclosed are methods of use of the claimed compositions and kits comprising the claimed compositions.
Absstract of: US20260298917A1
0000 This document relates to methods and materials for detecting the presence or absence of misfolded polypeptides in a sample. For example, a sample (e.g., a biological sample or an environmental sample) can be exposed to nanoparticles (e.g., nanoparticles having a size of no more than 2 μm (e.g., no more than 1 μm) such as silica nanoparticles (siNPs) having a size of no more than 2 μm (e.g., siNPs having a size of no more than 1 μm)) during a seeded amplification assay to accelerate the aggregation of misfolded polypeptides present in the sample into fibrils and/or polypeptide aggregates (e.g., globular polypeptide aggregates). In some cases, methods and materials provided herein can be used to determine if a mammal (e.g., a human) has a proteinopathy based, at least in part, in the presence or absence of misfolded polypeptides in a sample obtained from the mammal.
Absstract of: US20260297525A1
Disclosed herein are methods of expanding populations of patrolling monocytes in vitro and in vivo for treatment of sickle-cell disease (SCD), reducing pain and vaso-occlusive events in SCD patients, promoting wound healing, reducing tumor metastases, and treating vascular inflammatory conditions in subjects in need thereof.
Absstract of: US20260294329A1
0000 A non-invasive device for detecting Alzheimer's Disease-associated pathologies, comprising a fundus camera comprising a spectral reflectance imaging unit that includes a broadband light source and a light sensor and a lens assembly to focus light from the broadband light source onto a fundus of an eye, and one or more processors to detect reflected and/or backscattered light from the eye, illuminated by the broadband light source, using the light sensor for determining spectral reflectance information, generate a plurality of spectral reflectance maps comprising counts of reflected and/or backscattered light at a different wavelength or a different range of wavelengths, assign a weight to each of the spectral reflectance maps, and determine one or more regions of interest from the weighted spectral reflectance maps as being a potential Alzheimer's Disease-associated pathology based on a detection of one or more biomarkers indicative of Tauopathy.
Absstract of: KR20260143120A
0001a 본원은 LAMP1(Lysosome-Associated Membrane Protein 1) 및 OPTN(Optineurin)을 유효성분으로 포함하는, 신경 퇴행성 질환 진단용 바이오마커 조성물에 관한 것이다.
Absstract of: KR20260143067A
본 발명은 퇴행성 뇌질환 치료제 스크리닝용 TDP-43 변이체에 관한 것으로, TDP-43의 특정 영역 돌연변이를 통해 병리적 응집체인 아밀로이드 섬유 형성을 안정적으로 유도함으로써 실제 퇴행성 뇌질환의 병리 현상을 정확히 모사하는 질환 모델을 제공할 수 있다. 또한, 1,6-hexanediol에 대한 저항성을 갖는 고체상의 응집체를 형성하여, 액상 응집체의 병리적 고체상 전이를 제어할 수 있는 치료제 후보 물질을 신속하고 효율적으로 선별할 수 있다. 또한, 효모 및 포유동물 세포 시스템을 이용한 다각적 스크리닝을 통해 약물의 효능 및 세포 독성을 동시에 평가할 수 있는 신뢰성 높은 약물 탐색 플랫폼으로 활용할 수 있다.
Absstract of: EP4814494A1
Provided is a method for identifying molecules and compounds involved in the modulation of lipid synthesis and uptake, wherein said molecule or compound blocks or activates SREBP maturation, comprising contacting cells with a molecule or compound to be tested and observing the presence or absence of domains in the endoplasmic reticulum membrane formed by cholesterol esters with cholesterol or, alternately, localizing SREBP proteins within the cell after said contacting, wherein the molecule or compound is identified as an inhibitor of SREBP maturation when ER domains form within the cell or, alternately, SREBP signal is localized more in the endoplasmic reticulum, whereas the molecule or compound is identified as an activator of SREBP maturation when ER domains are absent or, alternately, SREBP signal is localized more in the nucleus or when its target genes are elevated.
Absstract of: WO2025059486A1
The present disclosure provides antibodies that specifically bind to human TDP-43 and methods of using these antibodies to treat patients with TDP-43-related diseases, including Amyotrophic Lateral Sclerosis (ALS).
Absstract of: CN122833160A
本发明涉及生物医药技术领域，尤其是涉及基于CD9的PASC相关心血管系统症状风险评估应用。本发明提供了一种以CD9为核心分子标志物的风险评估体系，该体系能够在常规检测手段难以提供充分解释的情况下，为PASC相关心血管系统症状风险评估提供客观、可量化的分子层面参考依据。
Absstract of: CN122836171A
本发明提供了用于测定外泌体蛋白的试剂在制备用于确定受试者衰老进程、用于在受试者中鉴定无症状期阿尔茨海默病和/或用于在受试者中区分无症状期阿尔茨海默病与正常衰老的试剂盒中的用途，其中，所述外泌体蛋白包括：C1QC、CO9、GP1BB、RSU1、A0A0G2JRQ6和ADA10。本发明基于六种特定外泌体蛋白的表达水平的动态变化速率分析，可精准区分无症状阿尔茨海默病与正常衰老，适用于AD早期筛查、MCI患者分层管理、疾病进展监测及健康体检，具有重要的临床实用价值和应用前景。
Absstract of: CN122832097A
本发明公开了抗神经丝轻链蛋白的单克隆抗体及其应用，属于单克隆抗体技术领域，具体涉及抗神经丝轻链蛋白的单克隆抗体、抗体对及其在检测试剂盒中的应用；该单克隆抗体包括单克隆抗体2H12和单克隆抗体6E7。本发明提供的单克隆抗体具有高度特异性、高结合力和高亲和力，将其应用于制备神经丝轻链蛋白的免疫检测试剂，有助于显著提升免疫检测试剂的热稳定性，增强其抗钩状效应能力，提高对神经丝轻链蛋白的检测灵敏度和精密度，为神经系统疾病的临床诊断提供了可靠的工具。
Absstract of: CN122836331A
本发明涉及生物医药领域，公开了ATP6V0A1 K303琥珀酰化位点的应用，包括ATP6V0A1 K303琥珀酰化位点在制备用于筛选治疗神经退行性疾病的候选药物的试剂盒中的应用、筛选治疗神经退行性疾病的候选药物的体外方法以及用于筛选治疗神经退行性疾病的候选药物的试剂盒，ATP6V0A1蛋白的氨基酸序列如SEQ ID NO:1所示，K303位点为第303位赖氨酸，检测剂包括用于LC‑MS/MS检测修饰肽段NWFVKSuccinylVR的试剂。本发明通过将该位点琥珀酰化修饰水平用于候选药物筛选，使筛选结果与该位点琥珀酰化修饰水平相对应，为筛选使该位点修饰水平升高的候选药物提供技术基础。
Absstract of: CN122832039A
0001 本发明公开了一种靶向补体C5的多肽及其应用和产品，属于多肽制备技术领域。本发明首次提供了一种C5靶向多肽（命名为C548），该多肽可显著抑制炎症状态下膜攻击复合物（MAC）的组装，有效减轻炎症介导的组织损伤，为自身免疫性疾病及其他补体异常相关疾病提供了一种潜在的替代抗体治疗策略。
Absstract of: US20260298944A1
0000 Provided is a method for measuring a polypeptide aggregate in a sample, wherein the method comprises obtaining information regarding a concentration of the polypeptide aggregate in the sample using a calibrator, and the calibrator comprises a complex comprising: an oligopeptide comprising an epitope of the polypeptide aggregate; a hydrophilic polymer chain not comprising the epitope; and a carrier particle.
Nº publicación: CN122827656A 29/09/2026
Applicant:
汕头大学医学院第二附属医院
Absstract of: CN122827656A
本发明涉及磁共振成像技术利用，公开了一种基于H2O2含量检测的神经退行性疾病进展评估方法及系统，方法包括以下步骤：对最常见的神经退行性疾病阿尔兹海默病转基因APP/PS1小鼠模型进行H2O2含量的在体动态监测，得到动态监测结果；设置若干个监测时间点；在每个监测时间点利用，结合所述VDMP‑CEST序列和非均匀采样法对所述患者进行扫描；扫描时采用针对H2O2优化的饱和脉冲参数；基于扫描得到的数据，利用基于水信号参考的CEST定量方法，定量每个监测时间点H2O2的CEST信号强度。
BOPI
Electronic site
